Alteogen and Daiichi Sankyo Forge New Partnership
Alteogen Inc. has embarked on an exciting journey by entering into an exclusive license agreement with Daiichi Sankyo. This partnership focuses on the development and commercialization of an innovative subcutaneous version of a leading cancer treatment, ENHERTU. This strategic collaboration is not just about two companies working together; it represents a landmark advancement in the field of antibody-drug conjugates (ADCs).
About the License Agreement
As part of the terms under this agreement, Daiichi Sankyo will obtain the worldwide rights to leverage ALT-B4. This novel hyaluronidase employs Alteogen's pioneering Hybrozyme™ Technology, which models a new approach to cancer treatment by enabling a formulation that allows drugs, previously administered via intravenous infusion, to be given subcutaneously.
This innovative approach is anticipated to enhance patient comfort and convenience significantly. Alteogen stands to receive both an upfront payment and further potential revenue through milestone payments that will be activated upon Daiichi Sankyo reaching specific developmental and regulatory achievements.
Understanding ALT-B4 Technology
ALT-B4 is Alteogen's proprietary human recombinant hyaluronidase enzyme created through its advanced Hybrozyme™ technology. This mechanism efficiently hydrolyzes hyaluronan in the extracellular matrix, making it possible to administer large volumes of drugs subcutaneously. This advancement in drug delivery methods opens new avenues in therapeutic administration for healthcare providers and patients alike.
Introducing Alteogen Inc.
Founded in 2008, Alteogen Inc. is a biopharmaceutical company with its roots in South Korea. Focused on the development and commercialization of innovative biologics, the company has developed a variety of products including biosimilars, biobetters, and ADCs. Alteogen's advanced platforms, NexP™-fusion and NexMab™, are fundamental to its pipeline, driving the creation of next-generation therapeutics to address various diseases.
Innovative Therapies on the Horizon
With a robust portfolio of clinical-stage drugs, Alteogen aims to meet the high medical needs of patients. The collaboration with Daiichi Sankyo aims to dominate in the area of ADC development, potentially showcasing novel treatment options for those battling cancer.
Looking Ahead: The Future of Cancer Treatment
The collaboration between Alteogen and Daiichi Sankyo signifies a move towards more accessible cancer treatments. As they advance through the development phases, the healthcare community remains hopeful for the potential benefits a subcutaneous administration method will entail.
Frequently Asked Questions
What is the main goal of the Alteogen and Daiichi Sankyo partnership?
The partnership aims to develop and commercialize a subcutaneous version of the cancer treatment ENHERTU, leveraging Alteogen's ALT-B4 technology.
What does ALT-B4 technology do?
ALT-B4 is a hyaluronidase enzyme that allows for larger volumes of drugs to be administered subcutaneously, improving convenience for patients traditionally receiving IV therapy.
How does this deal impact Alteogen's future?
This deal enhances Alteogen's position in the biopharmaceutical market, providing significant financial benefits and paving the way for cutting-edge therapeutic developments.
What types of products does Alteogen develop?
Alteogen focuses on novel biologics such as antibody-drug conjugates, biosimilars, and biobetters, primarily targeting serious health needs in oncology.
When was Alteogen founded?
Alteogen was founded in 2008 and has since expanded its operations significantly, now being listed on the KOSDAQ stock exchange.
